Clinical trial
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
NCT00299156 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00299156 |
|---|---|
| Title | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome |
| Official title | Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia |
| Intervention type | Drug |
| Interventions | Clofarabine |
| Enrollment | 65 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Mar 6, 2006 |
| Last update posted | Nov 3, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: